D&D Pharmatech, listed on the KOSDAQ under ticker 347850, announced on July 21, 2026, that 12-week results from its randomized Phase 2 DD01-DN-02 trial of zabopegdutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis had been published in The Lancet Gastroenterology & Hepatology. The peer-reviewed findings associate the investigational once-weekly dual GLP-1 and glucagon receptor agonist with substantial reductions in liver fat, liver stiffness and fibrosis-related biomarkers compared with placebo.
The publication gives greater scientific visibility to data that D&D Pharmatech had previously disclosed and that investigators presented at the 2025 Liver Meeting. It does not constitute regulatory approval, nor does it turn a relatively small Phase 2 study into confirmatory evidence, but it strengthens the credibility of the early non-invasive efficacy package supporting further development.
The central scientific proposition is that zabopegdutide may begin improving liver measures before substantial weight loss occurs. That possibility could matter in a MASH market where developers must distinguish liver-specific activity from the broader metabolic benefits already associated with incretin therapies. However, the weight-independent analysis remains supportive rather than definitive, and D&D Pharmatech will need a substantially larger late-stage programme to establish the candidate’s clinical and commercial position.
What does peer review add to the previously disclosed zabopegdutide Phase 2 results?
DD01-DN-02 was a randomized, double-blind, placebo-controlled Phase 2 study conducted at 12 centres in the United States. It enrolled 67 overweight or obese adults with MASLD or MASH and significant liver fat, with 33 participants assigned to zabopegdutide and 34 to placebo.
Participants in the active-treatment group received 20 mg once weekly for two weeks before moving to a 40 mg weekly maintenance dose. Zabopegdutide is a pegylated peptide with an approximately eight-day half-life and a biodistribution profile intended to favour hepatic exposure.
The trial’s primary 12-week endpoint was the proportion of participants achieving at least a 30% relative reduction in liver fat measured by magnetic resonance imaging proton density fat fraction, commonly known as MRI-PDFF. This is a useful non-invasive measure of hepatic steatosis and an established early development endpoint, but it is not itself proof that a therapy prevents cirrhosis, liver failure or other clinical outcomes.
At Week 12, 75.8% of participants receiving zabopegdutide achieved at least a 30% reduction in liver fat, compared with 11.8% receiving placebo. The difference was statistically significant, with a reported p-value below 0.0001.
The response extended beyond the primary threshold. D&D Pharmatech reported that 72.7% of treated participants achieved a liver fat reduction greater than 50%, while 57.6% achieved a reduction greater than 70%. Nearly half, or 48.5%, reached a liver fat fraction below 5%, compared with none in the placebo group.
Mean relative liver fat declined by 62.3% with zabopegdutide and 8.3% with placebo. Improvements were also reported in magnetic resonance elastography, liver enzymes, glycaemic measures, lipids and fibrosis-related biomarkers, including PRO-C3 and the Enhanced Liver Fibrosis score.
Peer review matters because it places the study design, statistical methods and findings within a more rigorous scientific framework than a company announcement. Even so, the publication primarily validates the reporting of the 12-week dataset. It should be understood as an important evidence-quality upgrade rather than a new clinical readout.
Does the weight-independent analysis establish a direct effect on the liver?
The most commercially interesting part of the publication is the relationship between liver improvement and weight loss. Average weight reduction with zabopegdutide was approximately 3.8% at 12 weeks and 6.4% at 24 weeks, a slower trajectory than the reduction in liver fat.
Among participants who lost less than 5% of their baseline body weight by Week 12, liver fat declined by 37.4% and liver stiffness measured by magnetic resonance elastography declined by 19.2%. Participants who lost at least 5% of their body weight recorded a larger 81.1% reduction in liver fat.
These findings are consistent with a combination of weight-dependent and weight-independent activity. The glucagon receptor component is intended to increase lipid mobilisation and hepatic fat metabolism, while GLP-1 receptor agonism supports glycaemic control, appetite regulation and weight reduction.
However, a subgroup relationship does not establish causation or prove a direct hepatic mechanism. Weight change, treatment exposure, baseline disease severity and metabolic response may interact in ways that are difficult to separate in a 67-person study. The analysis may strengthen the mechanistic rationale, but it does not demonstrate that glucagon activity independently caused the liver improvements.
The claim also needs careful competitive context. Exploratory analyses of semaglutide in MASH have likewise suggested that liver benefits may not be explained entirely by weight reduction. D&D Pharmatech therefore cannot establish differentiation merely by showing activity among participants with less than 5% weight loss.
A credible differentiation case will require a prespecified analysis in a larger trial, consistent effects across fibrosis stages and evidence that the liver response is maintained after accounting for weight loss and other metabolic changes.
How strongly do the non-invasive results predict meaningful histological improvement?
MRI-PDFF is responsive and useful for detecting changes in liver fat, while magnetic resonance elastography and circulating fibrosis biomarkers can help assess liver stiffness and fibrotic activity. Together, movement across several independent measures gives the zabopegdutide findings more biological coherence than an isolated improvement in one laboratory value.
At Week 12, mean liver stiffness declined by 19.7% with zabopegdutide and 7.2% with placebo. Among participants with F2 or F3 fibrosis, the corresponding reductions were 20.1% and 8.7%. Alanine aminotransferase also improved, with larger relative reductions in the active-treatment group through Weeks 12 and 24.
These results raised the possibility that the early non-invasive response would translate into histological improvement. D&D Pharmatech subsequently reported positive 48-week biopsy findings in May 2026, but those later results remain separate from the newly published 12-week paper.
In the company-reported Week 48 per-protocol analysis, 50% of 16 evaluable zabopegdutide recipients achieved at least a one-stage fibrosis improvement without worsening of MASH, compared with 15.8% of 19 placebo recipients. MASH resolution without worsening of fibrosis occurred in 62.5% and 5.3%, respectively. A combined fibrosis improvement and MASH resolution endpoint was reached by 37.5% of treated participants and 5.3% of placebo recipients.
Those results are encouraging because fibrosis improvement and MASH resolution are directly relevant to late-stage regulatory development. Yet the analysis involved only 35 protocol-compliant participants with paired biopsies, which leaves considerable uncertainty around the precision and generalisability of the response estimates.
The difference between an early signal and a development-ready conclusion is therefore substantial. A Phase 3 trial will need enough participants to evaluate histological responses using a rigorous missing-data strategy, demonstrate consistency across patient subgroups and provide a more reliable safety database.
Will the two-week titration remain an advantage when zabopegdutide enters larger trials?
D&D Pharmatech has highlighted the ability to reach the 40 mg maintenance dose after only two weeks of titration. A short escalation schedule could become a practical advantage if it allows patients to reach a therapeutically active exposure more quickly without producing unacceptable gastrointestinal toxicity.
The Phase 2 findings show that tolerability still requires close attention. Nausea was reported in 54.5% of participants receiving zabopegdutide and 17.6% receiving placebo. Constipation occurred in 30.3% and 11.8%, while diarrhoea affected 27.3% and 17.6%, respectively.
Decreased appetite was reported in 24.2% of treated participants, vomiting in 18.2% and fatigue in 18.2%. Three participants discontinued zabopegdutide because of gastrointestinal adverse events.
These events were described as non-severe, transient and self-limiting, but that wording does not make them clinically irrelevant. A discontinuation rate caused by gastrointestinal toxicity can affect adherence, real-world persistence and prescribing preferences, particularly when clinicians have several metabolic and liver-directed therapies to consider.
A larger programme must clarify whether the two-week titration remains suitable for patients with different body weights, diabetes status, fibrosis stages and concomitant medications. Dose selection will be particularly important because the Phase 2 study evaluated one active maintenance dose rather than establishing a detailed efficacy and tolerability curve across several dose levels.
Longer follow-up will also be needed to characterise less frequent adverse events and risks that a 67-person trial cannot reliably detect. The Phase 2 safety profile supports continued development, but it is not yet broad enough to support conclusions about routine clinical use.
How does zabopegdutide fit into a MASH market that already has approved therapies?
Zabopegdutide is entering a fundamentally different market from the one that existed when many MASH programmes began development. The United States now has two approved therapeutic options for adults with noncirrhotic MASH and moderate to advanced fibrosis consistent with stages F2 to F3.
Madrigal Pharmaceuticals’ Rezdiffra, or resmetirom, is an oral liver-directed thyroid hormone receptor beta agonist. Novo Nordisk’s Wegovy, or semaglutide 2.4 mg, gained an additional United States indication for noncirrhotic MASH with F2 to F3 fibrosis in August 2025.
These approvals raise the evidentiary and commercial bar for later entrants. A new injectable therapy may need to offer a compelling combination of histological efficacy, metabolic benefit, tolerability, dosing convenience and patient selection value. It may also need to demonstrate how it fits alongside established obesity, diabetes and liver-disease treatment pathways.
The competitive field includes other GLP-1 and glucagon receptor dual agonists, notably Boehringer Ingelheim’s survodutide, which is in Phase 3 development. This means the mechanism itself will not provide exclusive differentiation.
Cross-trial comparisons remain unreliable because studies differ in baseline fibrosis, biopsy scoring, endpoint definitions, treatment duration and handling of missing data. The current results therefore cannot establish that zabopegdutide is superior to resmetirom, semaglutide, survodutide or other MASH candidates.
The stronger strategic possibility is that zabopegdutide could offer combined liver and metabolic activity with a relatively rapid onset. Whether that profile is commercially meaningful will depend on Phase 3 evidence, not on comparisons assembled from unrelated Phase 2 datasets.
What must D&D Pharmatech demonstrate before zabopegdutide can enter late-stage development?
The United States Food and Drug Administration granted zabopegdutide Fast Track designation for MASH in 2024. That designation can support more frequent regulatory engagement and potentially facilitate review, but it is not an approval and does not confirm that the existing evidence is sufficient for registration.
D&D Pharmatech has said it intends to advance the programme into late-stage development. The next important disclosures should include the proposed target population, dose strategy, statistical assumptions, treatment duration and biopsy endpoints for the next trial.
The company must also determine whether it can move directly into Phase 3 or whether additional dose-ranging work is necessary. That decision will affect development time, trial cost and confidence that the selected dose offers the best balance between hepatic activity and gastrointestinal tolerability.
Manufacturing will become more consequential as the programme expands. A pegylated peptide intended for chronic weekly administration requires reproducible production, analytical control, stability data and scalable supply. Positive Phase 2 efficacy does not remove those chemistry, manufacturing and controls requirements.
Commercial capability is another consideration. D&D Pharmatech would be competing against companies with established metabolic-disease sales networks, payer relationships and manufacturing infrastructure. A development or commercial partnership could reduce execution risk, although the company has not made such an arrangement a prerequisite for the programme.
Why has D&D Pharmatech stock weakened despite the positive clinical narrative?
D&D Pharmatech shares were quoted around 59,900 won on July 22, compared with the previous session’s 61,000 won. The stock had fallen about 18.5% over the preceding week and approximately 46% over one month, although it remained around 68% higher over the previous year.
The shares were trading well below their June 2026 high of 116,600 won but remained above the lower end of their 52-week range of 29,375 won to 116,600 won. The company’s market capitalisation was approximately 2.8 trillion won.
That performance suggests investors are distinguishing between clinical promise and the cost, time and uncertainty of late-stage execution. The May biopsy announcement represented a more substantial de-risking event because it disclosed new histological results. The July publication provides external scientific validation, but it largely concerns data that the market had already seen.
For D&D Pharmatech, publication in a leading peer-reviewed journal is therefore an important credibility milestone rather than a decisive value inflection point. The programme’s next major test is whether the rapid non-invasive response and small per-protocol biopsy signal can be reproduced in a well-powered late-stage population.
Zabopegdutide now has a coherent Phase 2 story linking liver fat reduction, liver stiffness, fibrosis biomarkers and later histological improvement. What it does not yet have is confirmatory evidence that the effect is durable, broadly reproducible and sufficiently differentiated to earn a place in an increasingly competitive MASH treatment market.
